Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis

Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease

“…Eight articles were included for this clinical question. Children with cystic fibrosis are at risk for severe RSV infections and, therefore, they are more likely to require hospitalization and intensive care . The effectiveness and safety of palivizumab in children with cystic fibrosis have not been established.…”

“…The effectiveness and safety of palivizumab in children with cystic fibrosis have not been established. Only one randomized trial is included in the Cochrane review of Robinson et al, but it was published only as abstract. This is a double‐blind, placebo‐controlled trial conducted in 186 children (mean age: 12.8 months) with cystic fibrosis who received 15 mg/kg palivizumab or placebo monthly over 5 months in one RSV season.…”

Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease

“…Eight articles were included for this clinical question. Children with cystic fibrosis are at risk for severe RSV infections and, therefore, they are more likely to require hospitalization and intensive care . The effectiveness and safety of palivizumab in children with cystic fibrosis have not been established.…”

“…The effectiveness and safety of palivizumab in children with cystic fibrosis have not been established. Only one randomized trial is included in the Cochrane review of Robinson et al, but it was published only as abstract. This is a double‐blind, placebo‐controlled trial conducted in 186 children (mean age: 12.8 months) with cystic fibrosis who received 15 mg/kg palivizumab or placebo monthly over 5 months in one RSV season.…”

Use of palivizumab in infants and young children with severe respiratory disease: A delphi study

“…35 According to Winterstein et al 36 , RSV hospitalization incidence for RSV infection in CF patients seems to be low and, though unadjusted and adjusted RSVhospitalization incidence rates suggested potentially positive effects of palivizumab, results are inconclusive due to small event rates. On the other hand, according to Robinson et al 37 , it is not possible to draw conclusions on the safety and tolerability of RSV prophylaxis with palivizumab in infants with cystic fibrosis because no good trials have been done to access this point, but it seems that in CF patients the overall incidence of adverse events is similar to other groups. On a similar way, there is currently no evidence from randomized studies that influenza vaccine given to patients with cystic fibrosis is of benefit to them.…”

Palivizumab and Long-term Outcomes in Cystic Fibrosis

“…7 At a 12-month follow-up, proportions of infants with positive culture results for P aeruginosa were similar, as were weight-to-height ratios and rates of RSV hospitalizations. 5 treatment. Our propensity scores may not have adjusted completely for indication bias and could only include measured confounders.…”

Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease

“…Eight articles were included for this clinical question. Children with cystic fibrosis are at risk for severe RSV infections and, therefore, they are more likely to require hospitalization and intensive care . The effectiveness and safety of palivizumab in children with cystic fibrosis have not been established.…”

“…The effectiveness and safety of palivizumab in children with cystic fibrosis have not been established. Only one randomized trial is included in the Cochrane review of Robinson et al, but it was published only as abstract. This is a double‐blind, placebo‐controlled trial conducted in 186 children (mean age: 12.8 months) with cystic fibrosis who received 15 mg/kg palivizumab or placebo monthly over 5 months in one RSV season.…”

Use of palivizumab in infants and young children with severe respiratory disease: A delphi study

“…35 According to Winterstein et al 36 , RSV hospitalization incidence for RSV infection in CF patients seems to be low and, though unadjusted and adjusted RSVhospitalization incidence rates suggested potentially positive effects of palivizumab, results are inconclusive due to small event rates. On the other hand, according to Robinson et al 37 , it is not possible to draw conclusions on the safety and tolerability of RSV prophylaxis with palivizumab in infants with cystic fibrosis because no good trials have been done to access this point, but it seems that in CF patients the overall incidence of adverse events is similar to other groups. On a similar way, there is currently no evidence from randomized studies that influenza vaccine given to patients with cystic fibrosis is of benefit to them.…”

Palivizumab and Long-term Outcomes in Cystic Fibrosis

“…7 At a 12-month follow-up, proportions of infants with positive culture results for P aeruginosa were similar, as were weight-to-height ratios and rates of RSV hospitalizations. 5 treatment. Our propensity scores may not have adjusted completely for indication bias and could only include measured confounders.…”

Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease

“…Eight articles were included for this clinical question. Children with cystic fibrosis are at risk for severe RSV infections and, therefore, they are more likely to require hospitalization and intensive care . The effectiveness and safety of palivizumab in children with cystic fibrosis have not been established.…”

“…The effectiveness and safety of palivizumab in children with cystic fibrosis have not been established. Only one randomized trial is included in the Cochrane review of Robinson et al, but it was published only as abstract. This is a double‐blind, placebo‐controlled trial conducted in 186 children (mean age: 12.8 months) with cystic fibrosis who received 15 mg/kg palivizumab or placebo monthly over 5 months in one RSV season.…”

Use of palivizumab in infants and young children with severe respiratory disease: A delphi study

“…35 According to Winterstein et al 36 , RSV hospitalization incidence for RSV infection in CF patients seems to be low and, though unadjusted and adjusted RSVhospitalization incidence rates suggested potentially positive effects of palivizumab, results are inconclusive due to small event rates. On the other hand, according to Robinson et al 37 , it is not possible to draw conclusions on the safety and tolerability of RSV prophylaxis with palivizumab in infants with cystic fibrosis because no good trials have been done to access this point, but it seems that in CF patients the overall incidence of adverse events is similar to other groups. On a similar way, there is currently no evidence from randomized studies that influenza vaccine given to patients with cystic fibrosis is of benefit to them.…”

Palivizumab and Long-term Outcomes in Cystic Fibrosis

“…7 At a 12-month follow-up, proportions of infants with positive culture results for P aeruginosa were similar, as were weight-to-height ratios and rates of RSV hospitalizations. 5 treatment. Our propensity scores may not have adjusted completely for indication bias and could only include measured confounders.…”